Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 80425-0290

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 80425-0290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure of venlafaxine hydrochloride depicted as a skeletal formula with labeled functional groups, including a methoxy-substituted aromatic ring, a cyclohexane ring, and an N,N-dimethylamino group, alongside an HCl molecule indication.*

FDA Label Image

Label 1 (Venlafazine HCl Er 80425 0290 01)

Venlafaxine Hydrochloride ER 37.5 mg capsule label showing strength and dosage form. The label indicates the product is packed by Advanced Rx Pharmacy of Tennessee, LLC, and manufactured by Epic Pharma LLC. The label includes storage instructions, lot number, expiration date, and NDC details for the product.*

FDA Label Image

Label 2 (Venlafazine HCl Er 80425 0290 02)

Label for Venlafaxine Hydrochloride ER 37.5 mg capsules from Advanced Rx Pharmacy of Tennessee, LLC. The label includes dosing strength, route (oral), barcode, lot number, expiration date of 3/23/2023, and references NDC 80425-0290-02. The packaging is identified as #60 capsules with storage instructions.*

FDA Label Image

Label 3 (Venlafazine HCl Er 80425 0290 03)

Label for Venlafaxine Hydrochloride ER 37.5 mg capsule from Advanced Rx Pharmacy of Tennessee, LLC. Includes barcode, comparison to Effexor XR, lot number, expiration date, and EPIC Pharma LLC as NDC source.*

FDA Label Image

Fig 1 (Fig 1)

A pharmacokinetic fold change chart showing the effect of various interacting drugs on venlafaxine and its metabolites' Cmax and AUC values. The chart plots fold changes relative to a reference value with 90% confidence intervals and includes clinical recommendations such as avoid concomitant use, no dose adjustment, use with caution, and monitor blood pressure.*

FDA Label Image

Fig 2 (Fig 2)

A scatter plot chart showing the pharmacokinetic fold change (Cmax and AUC) of various analytes when co-administered with interacting drugs relative to reference values. The x-axis represents change relative to the reference value, and the y-axis lists interacting drugs and corresponding analytes like ethanol, diazepam, alprazolam, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium. The chart also includes a recommendation column addressing dose adjustments or clinical significance for each drug interaction.*

FDA Label Image

Fig 3 (Fig 3)

A plot showing fold change and 90% confidence intervals for the pharmacokinetics (Cmax, AUC, ODV) of venlafaxine in various special populations, including hepatic impairment, renal impairment, CYP2D6 metabolizer status, age over 60, and gender. The x-axis represents fold change relative to reference values, with dose adjustment recommendations provided for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.